思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 一目万相 成立于2021年7月，总部位于江苏苏州，是一家专注于工业与医疗领域多模态影像和人工智能深度 融合的科技公司。公司主营业务涵盖工业智能影像检测设备、医疗手术影像设备及手术智能辅助平台的研发、 生产与销售。凭借其核心团队在X射线产业近20年的深耕，一目万相在 底层X射线技术 方面拥有深厚的技术 积累和丰富的产业经验，其自研的X射线源能够有效解决工业和医疗领域的关键问题。 一目万相的核心技术是将最新的X射线成像技术与人工智能深度融合，能够高效获取高质量影像，实现高检测 质量。 目前，一目万相的X射线检测系统已在电子、汽车、航空航天、新能源、油气、材料、考古、科研等多个领域 得到广泛应用，市场表现良好。 融资历程 近日， 苏州一目万相科技有限公司 （以下简称"一目万相"）宣布完成新一轮融资，融资金额 达数千万 。本 轮融资由 苏创投 和 文教投·国发文鑫 管理的太仓市天使投资 ...

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 手回集团 港股｜挂牌上市 据IPO早知道消息，手回集团有限公司（以下简称"手回集团"） 计划于2025年5月30日正式 以"2621"为股票代码在港交所主板挂牌上市。 手回集团在本次IPO发行中总计发行24,358,400股股份。其中，香港公开发售获990.00倍认购，国 际发售亦获1.13倍认购。此外，手回集团在本次IPO发行中引入天津海泰集团和鹿驰资本两位基石投 资者，累计认购约4955万港元。以每股8.08港元的发行价计算，手回集团本次IPO募资总额为1.97 亿港元。 成立于2015年的手回集团作为一家中国人身险中介服务提供商，致力于通过人身险交易与服务平 台，在线为投保人和被保险人提供保险服务解决方案。 目前，手回集团旗下拥有小雨伞、咔嚓保和牛保100三大平台，从而赋能于不同销售场景中的保险交 易及服务——在小雨伞进行在线直接分销；在咔嚓保通过保险代理人进行分销；在牛保100在业务合 作伙伴的协助下进行分销。 根据弗若斯特沙利文的资料，按2023 年的长期人身险的总保费计算，手回集团是中 ...

Group 1: Company Overview - Insta360, a leading domestic action camera brand, is set to launch its IPO on the STAR Market, aiming to raise 464 million yuan for the construction of a smart imaging equipment production base and a research center in Shenzhen [1][2] - The IPO price is set at 47.27 yuan per share, with an online issuance scale of 6.56 million shares and a price-to-earnings ratio of 20.04 times [1] Group 2: Financial Performance - Insta360's revenue is projected to grow significantly from 20.41 billion yuan in 2022 to 55.74 billion yuan in 2024, achieving a compound annual growth rate of 65% [2] - Net profits are expected to rise from 4.07 billion yuan in 2022 to 9.95 billion yuan in 2024 [2] - Approximately 80% of Insta360's revenue comes from overseas markets, with international sales projected at 15.96 billion yuan, 29.03 billion yuan, and 42.23 billion yuan for the years 2022 to 2024, respectively [2] Group 3: Market Position - Insta360 holds a 67.2% market share in the consumer-grade panoramic camera sector, ranking first globally for six consecutive years [2] - In the broader action camera market, Insta360 has entered the top three, competing closely with GoPro and DJI, and has surpassed GoPro in sales in the first half of 2024 [2] Group 4: Industry Trends - The consumer electronics industry is witnessing rapid growth driven by technological innovations, with a notable focus on AI glasses expected to see significant product launches in 2025 [3][4] - The global sales of AI glasses are anticipated to exceed 5.5 million units in 2025, marking a 135% year-on-year increase [3] - Domestic manufacturers are actively releasing new AI glasses products to capture market opportunities, indicating a competitive landscape [3] Group 5: Market Sentiment - Recent performance of indices such as the Xinhua Manufacturing Overseas 50 and Xinhua TMT Overseas 50 reflects positive market sentiment, with some stocks experiencing notable gains due to revenue growth and industry optimism [4][5]

影石创新科技股份有限公司（简称"Insta360影石"），一家专注于智能影像设备的企业，近期已正式启动科创板上市申请流程，股票代码定为"688775"。 此次IPO，Insta360影石计划发行4100万股，每股定价47.27元，预计募集资金总额将达到19.38亿元。以发行价计算，公司市值预计约为170亿元。多家知 名投资机构参与了此次配售，包括中信证券投资有限公司、中金公司的两款员工参与战略配售集合资产管理计划、淡马锡富敦投资有限公司、上海灏裕信 息科技有限公司、立讯精密工业股份有限公司等，总认购金额达到3.88亿元。 | | | | | 获配股数 | | | | --- | --- | --- | --- | --- | --- | --- | | 序 | 参与战略配售的投资者名称 | 参与战略配售的 | 获配股数 | 占本次发 | 获配金额 | 限售期 | | 号 | | 投资者类型 | (股) | 行数量的 | (元) | (月) | | | | | | 比例 | | | | | | 参与科创板跟投 | | | | | | 1 | 中信证券投资有限公司 | 的保荐人相关子 | 1.269.303 | ...

在AI技术驱动下，一脉阳光的"一脉云"平台实现了影像数据的智能化应用，显著提升了诊断效率和准确 性。2025年4月份，公司旗下"CT胸部病变标注数据"成功登陆上海数据交易所，标志着其数据资产化迈 出关键一步。此外，子公司影禾医疗发布的医学影像基座模型在多项测试中表现优异(准确率超95%)， 为构建国内2.0时代的影像AI生态奠定了基础。公司还积极参与行业标准化建设，其主导的《医学影像 检查项目名称及编码标准》与国家医保局"医保影像云索引"政策高度契合，进一步巩固了行业话语权。 国际化布局，抢占全球蓝海市场。一脉阳光加速海外扩张，与医思健康(2138.HK)合作成立"一脉医思健 康科技联盟"，共同打造全球医疗科技供应链平台。目前，公司已在中国港澳地区站稳脚跟，并计划在 新加坡、马来西亚等地建立样板中心。董事长陈朝阳表示："未来五年，海外营收占比目标为30%。"这 一战略将充分利用中国医疗服务的性价比优势，实现全球化快速落地。 为支持战略实施，公司近期配股筹资1.95亿港元，资金将用于并购、海外拓展及研发。同时，一脉阳光 启动H股回购计划(上限1亿港元)，截至5月26日已回购596.38万港元，彰显管理层对长期价 ...

Company Overview - YingShi Innovation has initiated its public offering, with a total share capital of 360 million shares before the issuance and plans to issue 41 million shares, accounting for 10.22% of the post-issue total share capital [1] - The company focuses on the research, production, and sales of smart imaging devices such as panoramic cameras and action cameras [1] IPO Details - The subscription code for the public offering is 787775, with a subscription price set at 47.27 yuan per share and an issuance price-to-earnings ratio of 20.04 times [1] - The maximum subscription limit for a single account is 6,500 shares, requiring a minimum market value of 65,000 yuan in the Shanghai stock market for top-tier subscriptions [1] - The online issuance quantity is 6.56 million shares, with the total issuance quantity being 41 million shares [1] - The announcement of the winning numbers and payment date is scheduled for June 4, 2025 [1] Fundraising Allocation - The company plans to allocate 195.43 million yuan for the construction of a smart imaging device production base [1] - An additional 268.34 million yuan is designated for the establishment of a research and development center in Shenzhen [1] Financial Performance - Total assets for 2024 are reported at 502,081.23 million yuan, a significant increase from 304,651.82 million yuan in 2023 and 198,008.31 million yuan in 2022 [2] - Net assets have risen to 318,107.45 million yuan in 2024 from 218,580.99 million yuan in 2023 and 136,961.29 million yuan in 2022 [2] - Operating revenue for 2024 is 557,412.56 million yuan, up from 363,639.23 million yuan in 2023 and 204,113.36 million yuan in 2022 [2] - The net profit attributable to shareholders of the parent company for 2024 is 99,474.91 million yuan, compared to 82,957.51 million yuan in 2023 and 40,733.40 million yuan in 2022 [2] - Basic earnings per share for 2024 stand at 2.76 yuan, an increase from 2.30 yuan in 2023 and 1.13 yuan in 2022 [2] Research and Development - Research and development expenses for 2024 amount to 77,658.91 million yuan, compared to 44,768.03 million yuan in 2023 and 25,601.32 million yuan in 2022 [3] - The ratio of research and development expenses to operating revenue is 13.93% for 2024, up from 12.31% in 2023 and 12.54% in 2022 [3]

以下文章来源于硬氪 ，作者张子怡 硬氪 . 专注全球化、硬科技报道。36kr旗下官方账号。 市场格局尚未固化。 文 ｜ 张子怡 编辑 ｜ 袁斯来 来源｜ 硬氪（ID：south_36kr） 封面来 源 ｜ 企业官方 近日，硬氪从知情人士处独家获悉，大疆计划于7月推出其首款消费级全景相机DJI Osmo 360，全景相机赛道或将洗牌。 大疆这款产品早在2024年10月就通过美国联邦通信委员会（FCC）认证。从FCC披露的设计图来看，DJI Osmo 360采用双镜头对称结构，机身比市 面上主流全景相机更为紧凑。其内置1950mAh电池，与其运动相机Osmo Action 5 Pro规格一致。 图片来自FCC 目前主流的全景相机形态多为立杆式，在剧烈运动时，可能会出现不稳定的情况。根据FCC图片，大疆的产品更扁平，更容易收纳、携带和固定。 大疆Osmo 360 全景相机为影像领域的细分赛道，规模虽小，但成长迅速。 根据Frost & Sullivan统计，全球全景相机零售市场规模将从2017年的25.1亿元增长至2027年的78.5亿元，年复合增长超过10%。相比Go Pro等厂商， 大疆进入影像赛道稍晚，但无疑 ...

Core Viewpoint - DJI is set to launch its first consumer-grade 360-degree camera, the DJI Osmo 360, which will expand its imaging ecosystem and position it as a significant player in the panoramic camera market [1] Company Summary - The DJI Osmo 360 has received FCC certification as of October 2024, indicating that it has cleared essential regulatory hurdles for its official release [1] - The camera features a dual-lens symmetrical design and a compact body, enhancing portability compared to mainstream panoramic cameras [1] - It is equipped with a 1950mAh battery that operates effectively in temperatures ranging from 5℃ to 40℃, aligning with the specifications of the recently released Osmo Action 5 Pro [1] - DJI has established a strong presence in the action camera market, particularly with the Osmo Action 5 and Pocket 3, which have allowed it to capture market share from GoPro [3] Industry Summary - The global handheld smart imaging device market was valued at 36.47 billion yuan in 2023, with action cameras accounting for 86.2% of the market, while panoramic cameras represented only 13.8% [4] - The panoramic camera market is experiencing rapid growth, especially in China, which is expected to become a major consumer market [4] - In 2023, the Chinese panoramic camera market was valued at 1.06 billion yuan, making up 21.1% of the global market, with a year-on-year growth rate of 16% [4] - From 2020 to 2024, global shipments of panoramic cameras are projected to increase from 1.132 million units to 2.344 million units, with market size growing from 3.2 billion yuan to 5.85 billion yuan [4] - By 2025, global shipments of panoramic cameras are expected to reach 2.647 million units, with a market size of 6.61 billion yuan [4]

Core Insights - The chairman of Wandong Medical, Hu Ziqiang, resigned for personal reasons, effective immediately, and was succeeded by Ma Chibing, head of Midea Group's medical business, marking a significant personnel change in the company's leadership [2][5] - This change indicates a new phase in the integration of Midea Group's medical segment since acquiring Wandong Medical in 2021 [2] Financial Performance - In 2024, Wandong Medical's revenue is expected to grow by 23.26% to 1.524 billion yuan, but the net profit attributable to shareholders is projected to decline by 16.54% to 157 million yuan, with a gross margin decrease to 36.55% [5] - Over the past four years since Midea Group's acquisition, Wandong Medical has experienced a decline in net profit for three years, with both revenue and net profit decreasing in 2022 [5] Strategic Direction - Ma Chibing, the new chairman, has over 20 years of experience at Midea Group and has been tasked with leading the company's shift from "equipment manufacturing" to "ecosystem building" [5] - Under Ma's leadership, Wandong Medical will focus on an "AI + medical" strategy, aiming to position itself as a "Chinese solution provider" in the global medical imaging field, rather than directly competing with rivals like United Imaging [5]

内容概要：数字化X射线诊断系统（DR）是一种利用X射线和计算机技术进行影像采集和处理的医学影 像技术，已成为现代放射科的基础设备。作为医疗影像设备市场的重要组成部分，近年来，中国数字化 X射线诊断系统（DR）行业发展迅速，国内品牌在DR市场的竞争实力正在不断壮大。2024年，我国数 字化X射线诊断系统（DR）市场进口品牌的市场份额呈现下降趋势，国产化率再创新高，达到 68.78%。随着"设备更新"项目的逐步落实，相应的招采需求将陆续得到释放。"设备更新"热潮预计将推 动全国各级医院的老旧数字化X射线诊断系统（DR）进行全面的升级换代，进而在2025年为中高端数 字化X射线诊断系统（DR）市场带来新的增长机遇。中国数字化X射线诊断系统（DR）产业链正从"组 装制造"向"核心部件自主+智能化增值服务"升级，未来三年国产化率有望突破80%。 上市企业：联影医疗[688271]、万东医疗[600055]、迈瑞医疗[300760] 相关企业：西门子医疗、普爱医疗、安健科技、岛津、奕瑞科技、康众医疗、江苏感创、昆山医源、南 京普爱、宁波康力、东软医疗、深圳贝斯达、飞利浦、Trixell、万睿视、Vieworks、日本东丽 ...